1. Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization
- Author
-
Xiang Chen, Jiaoduan Li, Juan Tao, Nian Liu, Yeye Guo, Cong Peng, Jianda Zhou, Bei Yan, Xu Zhang, Jianglin Zhang, Hong Liu, Shuo Hu, and Mingzhu Yin
- Subjects
Amino Acid Transport System y+ ,Programmed Cell Death 1 Receptor ,Apoptosis ,Exosome ,B7-H1 Antigen ,Mice ,03 medical and health sciences ,0302 clinical medicine ,PD-L1 ,Drug Discovery ,Tumor Cells, Cultured ,Genetics ,medicine ,Animals ,Humans ,Immune Checkpoint Inhibitors ,Melanoma ,Molecular Biology ,Cell Proliferation ,030304 developmental biology ,Pharmacology ,0303 health sciences ,Gene knockdown ,biology ,Chemistry ,Glutamate receptor ,Macrophage Activation ,medicine.disease ,M2 Macrophage ,Xenograft Model Antitumor Assays ,Immune checkpoint ,Mice, Inbred C57BL ,Tumor progression ,030220 oncology & carcinogenesis ,Macrophages, Peritoneal ,biology.protein ,Cancer research ,Molecular Medicine ,Original Article ,Female - Abstract
Tumor cells increase glutamate release through the cystine/glutamate transporter cystine-glutamate exchange (xCT) to balance oxidative homeostasis in tumor cells and promote tumor progression. Although clinical studies have shown the potential of targeting programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) signaling in melanoma, response rates are low. However, it remains unclear how glutamate metabolism affects anti-PD-1/PD-L1 treatment efficacy in melanoma. Here, we demonstrated that although inhibition of xCT either by pharmacological inhibitor (sulfasalazine [SAS]), approved by US Food and Drug Administration (FDA) for inflammatory diseases, or genetic knockdown induced reactive oxygen species (ROS)-related death in melanoma cells, inhibition of xCT significantly reduced the efficacy of anti-PD-1/PD-L1 immune checkpoint blockade through upregulating PD-L1 expression via the transcription factors IRF4/EGR1, as a consequence, exosomes carrying relatively large amounts of PD-L1 secreted from melanoma cells resulted in M2 macrophage polarization and reduced the efficacy of anti-PD-1/PD-L1 therapy in melanoma. Taken together, our results reveal that inhibition of xCT by SAS is a promising therapeutic strategy for melanoma; on the other hand, SAS treatment blunted the efficacy of anti-PD-1/PD-L1 via exosomal PD-L1-induced macrophage M2 polarization and eventually induced anti-PD-1/PD-L1 therapy resistance.
- Published
- 2021
- Full Text
- View/download PDF